Moderna (MRNA) Stock Climbs As Q3 Earnings Turn Profitable

Moderna just ripped 5.3% higher to US$254.27 into the Q3 2026 print, yet the real story sits behind that green number on your screen. The biotech swung to a quarterly profit, posting US$162 million in net income on US$1.3b in sales, and that shift from heavy losses is what traders are trying to price in.

In the short term, this is a momentum spike. Over a longer horizon, the question is whether this first profitable quarter in a while justifies a rich P/S multiple and a volatile share price, or whether expectations have already run ahead of the earnings reality.

Like the shift to profit at Moderna but worried about paying up for a volatile story tied to a single blockbuster? You can balance that risk by comparing it with a broader group of financially stronger opportunities screened in our list of solid balance sheet and fundamentals stocks (24 results)

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs. Q3 2025): US$1,313 million vs. US$1,016 million (higher top line period on period)
• Net Income (Excl. Extra Items, Q3 2026 vs. Q3 2025): US$162 million profit vs. US$200 million loss (swing back into the black)
• Basic EPS (Q3 2026 vs. Q3 2025): US$0.40 vs. US$0.51 loss (return to positive per share earnings)
• Pipeline Breadth (Q3 2026 vs. Q3 2025): 9 Phase I, 16 Phase II, 7 Phase III products vs. 9 Phase I, 18 Phase II, 6 Phase III products (portfolio mix shifting slightly toward later stages)

Moderna just posted the first positive Phase III for an individualized cancer vaccine. Ask Charlie what Moderna’s first cancer vaccine win really changes.

Evaluating Whether Moderna’s Bull Story Is Taking Hold

Optimists argue Moderna can turn today’s portfolio into a broad, recurring business rather than a one hit COVID story.

"Some bullish analysts expect Moderna to turn its mRNA platform, respiratory vaccines and expanding oncology pipeline into a broad, multi-indication business that extends well beyond COVID vaccines."

Q3 moves that hypothesis from concept toward evidence. Moderna logged a profit alongside 29% year on year revenue growth, raised 2026 sales guidance, and cut cash cost guidance. Oncology is no longer only a slide in an investor deck after positive Phase 3 melanoma data and active regulatory work on intismeran. New approvals for mFLUSIVA and mCOFLU and progress on CEPI backed Ebola and bird flu programs show respiratory and pandemic lines broadening around that oncology pillar.

Not everyone reads the same price the same way. → See the lower figure this Narrative lands on, and how it gets there.

Moderna Bear Case: Execution Risk Still On Trial

The worry around Moderna is not the science. It is whether the broader respiratory and oncology plans can actually carry the heavier cost structure now in place.

"The extended norovirus Phase 3 trial, which failed to hit predefined early success criteria and now requires a fourth enrollment season, pushes out any potential launch window and increases trial exposure."

The latest quarter does not resolve that concern. Q3 profit and a higher 2026 revenue outlook come mostly from COVID and early flu traction. Norovirus contributes no near term sales, while R&D cuts and a 0% convertible highlight that execution gaps in that program still matter for the longer term earnings mix.

Hunt Quiet Fundamental Shifts

Moderna’s return to profit shows how quickly a single quarter can change sentiment for a business. The real opportunity is reviewing stocks that could be undervalued before the market adjusts expectations.

• Company 1 - 33% below our estimate - build a beverage platform expanding private label supply as retailers emphasize non-soda hydration.
• Company 2 - 31% below our estimate - shift high cost funding toward a deposit base as an automated lending engine replaces manual underwriting.
• Company 3 - 42% below our estimate - deploy cash recycling machines and branch-in-a-box systems as banks refit branches for lighter staffing.

That is three of the list. See the full list of 41 companies trading below our fair value estimates →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com